A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects
Latest Information Update: 02 May 2023
At a glance
- Drugs CSL 730 (Primary)
- Indications Autoimmune disorders; Epidermolysis bullosa; Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Sponsors CSL Behring
Most Recent Events
- 26 Apr 2023 Status changed from recruiting to discontinued.
- 28 Mar 2023 Planned End Date changed from 1 May 2023 to 1 Dec 2024.
- 28 Mar 2023 Planned primary completion date changed from 1 May 2023 to 1 Dec 2024.